Stock Analiz

Intellia Therapeutics, Inc. (NTLA) stock forecast and price target

Price $9.70 · data as of November 13, 2026

12-month price target

Average target$22.78
Upside / downside+134.8%
Analysts18
ConsensusBuy
Low $8.00Average $22.78High $61.00

Gold marker: average target · white marker: today’s price ($9.70)

Analyst ratings

Strong buy 1Buy 9Hold 6Sell 2Strong sell 2

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-3.27+14.2%$43M
Next fiscal year
ends December 31, 2027
$-2.70+17.5%$119M
Next quarter
ends December 31, 2026
$-0.78+6.3%$14M
Quarter after
ends March 31, 2027
$-0.83−2.3%$11M

Consensus of the analysts covering Intellia Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 6 lowered.

Frequently asked questions

What is the Intellia Therapeutics stock price target?

The average 12-month target from 18 analysts is $22.78, 134.8% above the current price of $9.70 Targets range from $8.00 to $61.00.

Is Intellia Therapeutics a buy according to analysts?

The consensus rating is “Buy” (1 strong buy, 9 buy, 6 hold, 2 sell, 2 strong sell). Ratings are opinions, not guarantees; this is not investment advice.

How much is Intellia Therapeutics expected to earn?

Analysts expect EPS of $-3.27 for the fiscal year ending December 31, 2026 and $-2.70 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.